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Background: Osteocalcin (OC) is a bone-specific protein produced primarily by osteoblasts during bone formation.
Besides its role in bone formation, osteocalcin may play a role in the regulation of energy metabolism and male
fertility. To interpret serum OC data, reference intervals adapted to a specific laboratory method are needed.
Methods: A healthy reference population was selected from the first follow-up of the Study of Health in
Pomerania. Serum OC concentrations were measured with the IDS-iSYS N-Mid Osteocalcin assay on the IDS-iSYS
Automated System (Immunodiagnostic Systems, Frankfurt am Main, Germany). The reference interval was defined
as the central 95% range (2.5th-97.5th percentile). Age-specific reference intervals were calculated by quantile
regression for 1107 men (25–79 years) and 545 premenopausal women (25–54 years). The reference interval for 498
postmenopausal women (50–79 years) was calculated irrespective of age.
Results: Median (1st-3rd quartile) serum OC concentrations were 15.4 ng/mL (12.0-19.4 ng/mL) in men, 14.4 ng/mL
(11.3-18.5 ng/mL) in premenopausal women, and 18.6 ng/mL (13.6-25.6 ng/mL) in postmenopausal women. Serum
OC concentrations were highest in men and premenopausal women aged 25–29 years, were stable during midlife,
and rose again after 65 years of age in men and at transition to menopause in women. Serum OC concentrations
were lower in women taking oral contraceptives or who were under hormone replacement therapy after
menopause and in subjects with diabetes mellitus or with body mass index < 18 or > 30 kg/m2 than in subjects
without these conditions.
Conclusions: We established sex-specific adult reference intervals for the serum OC concentration measured by the
IDS-iSYS N-Mid Osteocalcin assay.
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Bone is a dynamic tissue undergoing constant remodelling.
In healthy adults maintenance of bone mass is achieved by
coupling of bone formation and bone resorption pro-
cesses [1]. These processes can be assessed by determin-
ation of bone turnover markers (BTMs) [2]. Although
BTMs show promise for the determination of fracture
risk, current evidence is insufficient to recommend the
clinical application of BTMs in fracture risk prediction [3].* Correspondence: anke.hannemann@uni-greifswald.de
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distribution, and reproduction in any mediumIn addition to their potential role in fracture risk evaluation,
BTMs indicate rapid changes in bone metabolism after ini-
tiation of antiresorptive or anabolic osteoporosis therapy
[2,4,5]. It has been suggested that BTMs may aid selecting
the optimal therapy and medication dose but also to moni-
tor treatment compliance and efficacy in the individual pa-
tient [2,6].
There are several bone formation and resorption
markers [2]. According to the 2012 European guidance for
the diagnosis and management of osteoporosis in post-
menopausal women [3], the most informative BTMs for
osteoporosis monitoring are procollagen I N-terminal ex-
tension peptide and C-telopeptide breakdown products.ntral Ltd. This is an Open Access article distributed under the terms of the
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osteocalcin (OC). OC is a bone-specific protein produced
primarily by osteoblasts during bone formation [2].
Besides its role in bone formation, several studies
demonstrated a potential relevance of undercarboxylated
OC in energy metabolism [7,8] and male fertility [9,10].
Also correlations between total OC, including undercar-
boxylated and carboxylated OC, and fasting glucose
[11-13] or fasting insulin [12] were detected and it was
demonstrated that OC levels are lower in diabetic than in
healthy subjects [11,14].
Circulating OC concentrations vary according to age
and sex [15-19]. Previous studies suggested that young
adult men have higher levels than young women of the
same age [20,21], as they have longer and wider bones
and reach peak BMD later in life [17]. After peak BMD
is reached, serum OC concentrations decline in men
and women [15,17,19,22]. In middle-aged and elderly
men beyond 50–60 years of age, serum OC concentrations
become stable or increase slightly [15,16]. In premeno-
pausal women between 35–45 years of age serum concen-
trations of OC and other BTMs are stable and it has been
suggested, that female bone health is at its best at this age
[19,22]. In women at transition to menopause, serum OC
concentrations increase strongly [5]. Therefore, several
investigators proposed to use the lower half of the OC
reference interval for women between 35–45 years of age
as the target for antiresorptive therapy in postmenopausal
women [22-24].
There are several laboratory methods for OC measure-
ment, which may differ in various aspects including the
recognition of circulating OC fragments [25]. As the
different OC assays may yield different results, it is of
major importance to establish method-specific reference
intervals to adequately interpret serum OC concentra-
tions. Currently, most studies on reference intervals for
serum OC concentrations focused on premenopausal
women [19,22,23,26], while normative data for postmen-
opausal women [21] and men [16,21] are sparse. The
aim of our study was to provide sex- and age-specific
reference intervals for serum OC concentrations mea-
sured with the IDS-iSYS N-Mid Osteocalcin assay
obtained in healthy adults aged 25–79 years.
Methods
The Study of Health in Pomerania (SHIP)
SHIP is a population-based cohort study in the northeast
of Germany. Study design and sampling methods have
been previously described [27]. In short, for the baseline
study (SHIP-0) a representative sample of 7008 adults
aged 20–79 years was drawn from the population living in
the region of West Pomerania (n = 158,864). The study re-
gion comprised the three cities Greifswald, Stralsund and
Anklam and the surrounding 29 communities. Thebaseline examinations were conducted in 4308 men and
women between October 1997 and May 2001. Five years
later, between March 2003 and July 2006, the first follow-
up examination, designated as SHIP-1, was conducted
with 3300 participants being re-examined. The present
analyses are based on SHIP-1 data. Due to drop-out be-
tween baseline and follow-up examination, the SHIP-1
study population is not truly representative for the study
region. All participants gave written informed consent.
The study was reviewed by an external scientific review
board and conformed to the principles of the Declaration
of Helsinki as reflected by an a priori approval of the Ethics
Committee of the Board of Physicians Mecklenburg-West
Pomerania at the University of Greifswald.
Instruments and measurements
Information on socio-demographic characteristics and
medical histories was obtained by computer-aided per-
sonal interviews. Medication was classified using the
Anatomical Therapeutic Chemical Classification System
(ATC) code. Menopausal status was defined according to
age and self-reported menstrual cycling. All women youn-
ger than 40 years of age and all women between 40 and
60 years of age who reported menstrual cycling were de-
fined as premenopausal, all other women were defined as
postmenopausal. It was not possible to define perimeno-
pause as the respective information was not collected.
Non-fasting blood samples were taken from the cubital
vein of participants in the supine position between
8.00 a.m. and 8.00 p.m. Serum aliquots were stored
at −80°C. Serum OC concentrations were measured with
the IDS-iSYS N-Mid Osteocalcin assay on the IDS-iSYS
Multi-Discipline Automated Analyser (Immunodiagnos-
tic Systems Limited, Frankfurt am Main, Germany)
according to the instructions for use. This assay detects
the intact OC polypeptide (amino acids 1–49) and the
N-terminal-Mid OC fragment (amino acids 1–43). The
measurement range of the assay was 2–200 ng/mL. The
limits of blank and detection were 0.27 ng/mL. The limit
of quantitation was 1.57 ng/mL. As recommended by
the manufacturer, three levels of control material were
measured in order to verify a decent working mode.
During the course of the study, the coefficients of vari-
ation were 6.93% at low, 6.83% at medium, and 5.06% at
high serum OC concentrations in the control material.
Reference population
We selected a healthy reference population by excluding
all subjects with missing data on serum OC concentration
(n = 36), presence of or missing information on any of the
following conditions: renal disease defined as estimated
glomerular filtration rate (Cockcroft-Gault) <30 mL/min
(n = 30), hyperparathyroidism defined as serum para-
thyroid hormone concentration >120 pg/mL (n = 24),
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ranges [28] as serum thyroid-stimulating hormone con-
centration <0.25 mU/L and serum free thyroxine concen-
tration >18.9 pmol/L (n = 71), or a self-reported history of
cancer (n = 189), osteoporosis (n = 209), or liver disease
(n = 41). In addition to these subjects, we excluded further
participants with conditions known to affect bone metab-
olism including all pregnant women (n = 12), all subjects
with serum 25-hydroxy vitamin D concentration <10 μg/L
(n = 342), and all subjects (n = 85) who reported intake of
any of the following medication: bisphosphonates (ATC
M05BA, M05BB), selective estrogen receptor modulators
(ATC G03XC), vitamin D (ATC A11CC), calcitonin (ATC
H05BA), strontium ranelate (ATC M05BX03), parathyroid
hormone (ATC H05AA), testosterone (ATC G03BA02,
G03BA03), anticonvulsants (ATC N03A), heparin (ATC
B01AB), steroids (ATC H02AB), calcium (ATC A12A),
antiandrogens (ATC L02BB), or aromatase inhibitors
(ATC L02BG). Moreover, due to the small number of sub-
jects older than 79 years of age (n = 59 men and women)
we also excluded those subjects. This resulted in a male
reference population of 1107 subjects aged 25 to 79 years.
In females we differentiated between pre- and postmeno-
pausal women. As there were only few premenopausal
women older than 54 years of age (n = 3) and few post-
menopausal women younger than 50 years of age (n = 49)
these women were also excluded from the analyses. This
resulted in a reference population of 545 premenopausal
women aged 25 to 54 years and 498 postmenopausal
women aged 50 to 79 years.
Statistical analyses
Continuous data are expressed as median (1st-3rd quar-
tile) and nominal data are expressed as percentage. Group
comparisons were performed using Kruskal-Wallis tests.
One-way analysis of variance was used to test for signifi-
cant effects of month of blood sampling, and significant
effects of daytime of blood sampling on log-transformed
mean serum OC concentrations. P-values <0.05 were
considered statistically significant. To estimate reference
limits nonparametric quantile regression was used, a
method for estimating models for conditional quantile
functions [29]. Unlike the linear regression approach, this
method does not require that the data follow a Gaussian
distribution. A transformation of the dependent variable
was thus not necessary. To estimate the reference limits
for serum OC concentrations as a function of age, we
developed a polynomial model of the form f(age) = b +
b1*age + b2*age
2 + . . . + bd*aged. The highest degree d in
the polynomial was determined by consecutively adding
higher degree polynomials, until the added term was no
longer statistically significant. The age-related changes of
serum OC concentrations in men and premenopausal
women were modeled by fitting a quadratic equation. The2.5th and 97.5th percentiles of the OC distribution were
estimated for each single year of age. Subsequently, mean
values for five-year age groups were calculated. In post-
menopausal women serum OC concentrations did not
vary with age, thus an age-independent reference interval
is reported. All statistical analyses were performed with
SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
In 1107 male subjects from the reference population the
median serum OC concentration was 15.4 ng/mL (1st–3rd
quartile: 12.0–19.4 ng/mL). In 545 premenopausal women
the median serum OC concentration was 14.4 ng/mL
(1st–3rd quartile: 11.3–18.5 ng/mL) and in 498 postmeno-
pausal women the median serum OC concentration was
18.6 ng/mL (1st–3rd quartile: 13.6–25.6 ng/mL). Further
characteristics of the reference population are presented in
Table 1. Age-related changes in serum OC concentrations
are displayed in Table 2.
Throughout the calendar year there was little variation
in serum OC concentrations. In the entire reference popu-
lation the serum OC concentrations were lowest in March
(median 15.0 ng/mL; 1st-3rd quartile: 11.9-19.1 ng/mL)
and highest in December (median 16.9 ng/mL; 1st-3rd
quartile: 13.5-22.3 ng/mL) (Additional file 1: Figure S1).
Regarding daytime of blood sampling (Additional file 1:
Figure S2), we observed no statistically significant varia-
tions in serum OC concentrations.
Premenopausal women using oral contraceptives (ATC
G03A; n = 126) had significantly lower serum OC con-
centrations (median: 13.0 ng/mL; 1st-3rd quartile: 10.3-
16.7 ng/mL) than premenopausal women not using oral
contraceptives (median: 15.0 ng/mL; 1st-3rd quartile:
11.6-18.9 ng/mL; n = 419). Furthermore, postmenopausal
women using hormone replacement therapy (ATC G03C
G03D G03F; n = 48) had significantly lower serum OC
concentrations (median: 14.9 ng/mL; 1st-3rd quartile:
11.9-19.9 ng/mL) than women not using hormone re-
placement therapy (median: 19.1 ng/mL; 1st-3rd quar-
tile: 13.9-26.2 ng/mL; n = 450).
In addition, we found that men with diabetes mellitus or
body mass index (BMI) <18 or >30 kg/m2 had significantly
lower serum OC concentrations (median: 13.7 ng/mL;
1st-3rd quartile: 10.5-17.4, ng/mL; n = 391) than non-
diabetic, normal weight men (median: 16.4 ng/mL; 1st-3rd
quartile: 13.0-20.5, ng/mL; n = 716). Also pre- and post-
menopausal women with diabetes mellitus or BMI <18
or >30 kg/m2 had significantly lower serum OC concen-
trations (premenopausal women median: 13.7 ng/mL; 1st-
3rd quartile: 10.4-16.5 ng/mL; n = 105; postmenopausal
women median: 16.7 ng/mL; 1st-3rd quartile: 11.9-
22.3 ng/mL; n = 195) than non-diabetic, normal weight
pre- and postmenopausal women (premenopausal women
median: 14.6 ng/mL; 1st-3rd quartile: 11.5-18.8, ng/mL;
Table 1 Characteristics of the reference population
Characteristics Men (n = 1107) Women
Premenopausal (n = 545) Postmenopausal (n = 498)
Age [years] 53.0 (41.0 - 64.0) 39.0 (33.0 - 44.0) 62.0 (56.0 - 67.0)
BMI [kg/m2] 27.9 (25.5 - 30.7) 24.5 (22.1 - 28.1) 28.1 (25.0 - 32.1)
Diabetes mellitus [%] 10.1 0.92 13.1
Oral contraceptives (ATC G03A) [%] - 23.1 -
Hormone replacement therapy (ATC G03C G03D G03F) [%] - - 9.6
25-hydroxy vitamin D [μg/L] 19.2 (14.6 - 25.1) 20.0 (14.5 - 28.3) 18.2 (13.7 - 23.8)
Parathyroid hormone [pg/mL] 33.7 (25.7 - 43.2) 28.4 (20.8 - 37.5) 36.3 (27.4 - 45.4)
Osteocalcin [ng/mL] 15.4 (12.0 - 19.4) 14.4 (11.3 - 18.5) 18.6 (13.6 - 25.6)
BMI, Body Mass Index.
Continuous variables are presented as median (1st - 3rd quartile), dichotomous variables are presented as proportions.
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3rd quartile: 16.0-28.6, ng/mL; n = 255).
To account for the observed effects on the serum
osteocalcin concentration, reference limits were deter-
mined (1.) for the entire reference population and (2.) after
exclusion of women taking sex hormones for contracep-
tion or hormone replacement and subjects with diabetes
mellitus or BMI <18 or >30 kg/m2.
In men and premenopausal women reference limits
were modeled by quantile regression. The models were
fitted with parameters presented in Table 3. In postmeno-
pausal women reference limits were determined irrespec-
tive of age. Reference intervals for five-year age groups are
presented in Table 4. The respective reference curves are
presented in Figure 1. In men aged 25–49 years upper and
lower reference limits for serum OC concentrations de-
creased continuously with increasing age. In middle-aged
and older men the upper and lower reference limits were





n Serum OC concentration [ng/mL] Men
25-29 49 21.2 (16.5 - 25.0) Pr
30-34 79 18.9 (15.3 - 21.4)
35-39 113 17.4 (14.7 - 20.6)
40-44 113 16.9 (14.0 - 20.5)
45-49 123 14.5 (11.6 - 17.2)
50-54 127 13.5 (10.2 - 18.8)
Po
55-59 118 14.1 (11.2 - 17.8)
60-64 132 14.5 (11.4 - 18.1)
65-69 114 13.4 (10.8 - 17.2)
70-74 85 14.2 (10.4 - 18.5)
75-79 54 16.7 (12.3 - 20.0)
Values are presented as median (1st - 3rd quartile).premenopausal women the upper and lower reference
limits for serum OC concentrations decreased markedly
between 25–34 years of age and remained stable after an
age of 34 years. Previous studies [19,22] proposed that
antiresorptive therapy should lower serum OC concentra-
tions in postmenopausal women to the lower half of the
reference interval of premenopausal women between
35–45 years of age. In our study, the reference interval
for 35–44 year-old premenopausal women was 7.4-
30.8 ng/mL, the lower half of the reference interval was
(2.5th-50th percentile) 7.4-13.9 ng/mL.
The reference limits in subjects not taking oral contra-
ceptives or hormone replacement therapy, without diabetes
mellitus and with BMI between 18–30 kg/m2 (716 men,
329 pre- and 255 postmenopausal women) were higher
than the reference limits obtained in the whole reference
population (Table 4). This is particularly true for the upper
reference limits, whereas the lower reference limits were
less affected (Figure 2). In premenopausal women notups
Women
opausal status n Serum OC concentration [ng/mL]
e-menopausal 71 17.2 (13.2 - 21.8)
96 15.5 (12.2 - 19.0)
125 14.5 (10.4 - 18.5)
118 13.4 (10.2 - 16.5)
87 12.9 (10.6 - 16.2)
48 14.2 (11.4 - 17.3)
st-menopausal 81 18.9 (12.5 - 27.3)
107 20.6 (14.3 - 28.6)
131 17.9 (13.5 - 22.8)
87 19.5 (12.9 - 26.3)
57 18.8 (13.7 - 28.0)
37 18.2 (14.4 - 25.4)
Table 3 Parameter estimates with 95% confidence intervals (CI) for quantile regression models
Model Lower reference limit Upper reference limit
(2.5th percentile) (97.5th percentile)
Parameter estimate (95% CI) Parameter estimate (95% CI)
Men
Intercept 19.4778 (15.7036; 26.1654) 55.3758 (42.6834; 76.1057)
Age −0.3806 (−0.5235; -0.2307) −0.8982 (−1.9454; -0.3549)
Age2 0.0028 (0.0012; 0.0052) 0.0076 (0.0029; 0.0181)
Men, without diabetes mellitus and with BMI 18–30 kg/m2
Intercept 16.8043 (11.6050; 26.3003) 50.5885 (39.3315; 75.4833)
Age −0.2382 (−0.5940; -0.0961) −0.6898 (−2.2462; -0.2172)
Age2 0.0014 (−0.0001; 0.0048) 0.0058 (0.0010; 0.0158)
Women, premenopausal
Intercept 25.825 (2.6944; 32.5959) 73.8844 (−37.2837; 310.5797)
Age −0.8844 (−1.2162; 0.7307) −1.7612 (−12.3023; 4.2155)
Age2 0.0106 (−0.0169; 0.0145) 0.0169 (−0.0551; 0.1337)
Women, premenopausal without oral contraceptives, without diabetes mellitus, and with BMI 18–30 kg/m2
Intercept 46.8442 (1.4278; 53.8028) 62.0062 (−70.8969; 3609.508)
Age −1.8757 (−2.2815; 0.0366) −1.1167 (−66.4225; 6.5886)
Age2 0.0224 (−0.0006; 0.0279) 0.0104 (−0.0889; 0.8494)
BMI, Body Mass Index.
For postmenopausal women 2.5th and 97.5th percentiles were determined irrespective of age.







mellitus and with BMI
18–30 kg/m2 (N = 716)
Women All women (N = 545
premenopausal N = 498
postmenopausal)
Women without hormone intake,
without diabetes mellitus and
with BMI 18–30 kg/m2 (N = 440










25-29 11.2 - 36.7 11.4 - 36.2 Premenopausal 9.7 - 38.7 12.6 - 39.5
30-34 10.2 - 34.4 10.6 - 34.5 8.4 - 34.8 9.8 - 37.0
35-39 9.2 - 32.5 9.9 - 33.1 7.6 - 31.9 8.1 - 35.0
40-44 8.4 - 31.0 9.2 - 31.9 7.3 - 29.7 7.6 - 33.5
45-49 7.7 - 29.9 8.6 - 31.1 7.6 - 28.4 8.2 - 32.6
50-54 7.2 - 29.2 8.1 - 30.5 8.4 - 28.0 9.8 - 32.1
Postmenopausal (all ages) 8.0 - 40.9 10.4 - 43.8
55-59 6.8 - 28.8 7.7 - 30.3
60-64 6.6 - 28.8 7.3 - 30.3
65-69 6.5 - 29.2 7.0 - 30.6
70-74 6.5 - 30.0 6.7 - 31.2
75-80 6.7 - 31.2 6.5 - 32.1
Reference limits for men and premenopausal women were determined by quantile regression and are displayed for five-year age groups. For postmenopausal
women 2.5th and 97.5th percentiles were determined irrespective of age. Subjects with diabetes mellitus or BMI <18 or >30 kg/m2 and women using oral
contraceptives or hormone replacement therapy had significantly lower serum OC concentrations than normal weight subjects without diabetes mellitus and
women without intake of oral contraceptives or hormone replacement therapy. The exclusion of subjects with diabetes mellitus, BMI <18 or >30 kg/m2, and
women taking oral contraceptives or hormone replacement therapy shifted the distribution of serum osteocalcin concentrations and the reference intervals to
higher values.
Hannemann et al. BMC Endocrine Disorders 2013, 13:11 Page 5 of 9
http://www.biomedcentral.com/1472-6823/13/11
Figure 1 Reference curves for serum osteocalcin concentrations in men as well as pre- and postmenopausal women. Individual values
(dots) and reference curves for the median (dashed lines) as well as the 2.5th and 97.5th percentiles (solid lines) are displayed. Reference limits for
men and premenopausal women were determined by quantile regression. For postmenopausal women 2.5th and 97.5th percentiles were
determined irrespective of age.
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with BMI between 18–30 kg/m2 the reference interval for
35–44 year-old women was 7.8-34.2 ng/mL, and the lower
half of the reference interval was 7.8-14.4 ng/mL.
Discussion
We established reference intervals for serum OC concen-
trations measured with the IDS-iSYS N-Mid Osteocalcin
assay in a large cohort of subjects with European ancestry.
We observed age- and sex-specific differences in serum
OC concentrations in healthy adults. Next to age and sex,
the normative data was influenced by intake of oral con-
traceptives or hormone replacement therapy as well as by
altered anthropometry (BMI <18 or >30 kg/m2) and dia-
betes mellitus.Figure 2 Reference curves for serum osteocalcin concentrations from
Reference curves include (1.) all subjects from the reference population (so
postmenopausal women without hormone replacement therapy (dotted li
or >30 kg/m2 (dashed lines). Reference limits for men and premenopausal
women 2.5th and 97.5th percentiles were determined irrespective of age.The estimated reference intervals for men, as well as
pre- and postmenopausal women follow previously de-
scribed age-related patterns [5,17,19,22]. In premenopausal
women reference limits were highest in the youngest age
group of 25–29 years. In premenopausal women older than
34 years of age, reference intervals were relatively stable.
The relatively high serum osteocalcin concentrations in
premenopausal women below 30 years of age may indi-
cate that peak bone mass is not yet reached at this age,
while the stable and low serum osteocalcin concentra-
tions in premenopausal women aged 35 or older may indi-
cate that these women have reached skeletal maturity and a
phase of stable bone turnover [22]. Afterwards, at transi-
tion to menopause, the loss of estrogen results in a dis-
equilibrium between bone formation and bone resorptionthe whole reference population and from two subpopulations.
lid lines), (2.) premenopausal women not taking oral contraceptives or
nes) and (3.) all subjects without diabetes mellitus or with BMI <18
women were determined by quantile regression. For postmenopausal
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tions rise considerably, by about 50-150% [5]. Our data are
in line with these results: median serum OC concentrations
and serum OC reference limits increased strongly in post-
menopausal women compared to premenopausal women.
Especially the upper reference limit for postmenopausal
women (40.9 ng/mL) was markedly higher than the upper
reference limit for premenopausal women aged 50–54 years
(28.0 ng/mL). Male reference limits decreased between 25
to 49 years of age, were stable between 50 to 65 years of
age, and increased minimally in the late 6th and 7th decade
of life. The increase in serum OC reference limits in elderly
men was, however, not comparable to the increase ob-
served in females during transition to menopause.
In addition to the effects of age and sex, there may be
other factors influencing serum OC concentrations such
as the use of oral contraceptives [23,32,33], hormone re-
placement therapy [18,34], diabetes mellitus [35,36], and
BMI [18,23]. Furthermore, serum OC concentrations
were reported to be affected by calcium intake [19,37]
and to be subject to circadian [38,39], or seasonal varia-
tions [18,40,41]. The potential effects of these factors on
serum OC concentrations are controversial. While we
did not observe circadian or seasonal variations of serum
OC concentrations in our study population, our data
confirm the influence of oral contraceptives, hormone
therapy, diabetes mellitus, and BMI on serum OC con-
centrations. Overall, the examined factors had stronger
impacts on the upper than on the lower reference limits.
After exclusion of all subjects using oral contracep-
tives or hormone replacement therapy, with diabetes
or BMI < 18 or >30 kg/m2, the upper reference limits
increased by maximally 4.2 ng/mL in women and by ma-
ximally 1.5 ng/mL in men while the lower reference limits
increased by maximally 2.9 ng/mL in women and by max-
imally 0.9 ng/mL in men.
In general, female osteoporosis has been more intensively
investigated than male osteoporosis, probably because the
prevalence of osteoporotic fractures is much higher in
women than in men [42]. The focus on female osteoporosis
is reflected in the larger number of studies reporting female
[19,21-23,26] than male [21] reference intervals for serum
OC concentrations. For premenopausal women previous
studies report serum OC reference intervals based on data
from 153 women between 35–45 years of age from the
U.K. (7.0-28.3 ng/mL) [22], 82 women between 46–50 years
of age from Italy (1.91-4.87 ng/mL) [23], 765 women
between 35–45 years of age from Saudi Arabia (2.47 –
16.78 ng/mL) [19], and 475 women between 30–44 years
of age from Japan (2.0-7.6 ng/mL) [26]. In the study from
the U.K. [22] serum OC concentrations were measured
with an enzyme-linked immunosorbent assay (ELISA)
from Nordic Bioscience Diagnostics. In the Italian [23]
and Saudi Arabian studies [19] immunoassays from RocheDiagnostics were used, and in the Japanese study [26] an
immunoradiometric assay from Mitsubishi Kagaku Iatron
Inc. was used. Our reference interval for 35–44 year-old
premenopausal women (7.4-30.8 ng/mL) is in good agree-
ment with that reported for premenopausal women from
the U.K. [22], while those from Italy [23], Saudi Arabia
[19], and Japan are considerably lower [26]. It is well
known that different OC assays may yield different results
[25]. The main reasons for this include differences in rec-
ognition of circulating OC fragments and differences in
cross-reactivity to other molecules [25]. Next to differ-
ences in laboratory methods also sample handling influ-
ences the serum OC concentration, as it is sensitive to
freeze-thaw cycles and haemolysis [25]. In how far the la-
boratory methods and the sample handling contributed to
the differences in the serum OC reference intervals
reported above cannot be quantified in present study. Yet,
the differences between the laboratory methods may not
be large, as the assays used in the studies from the U.K.
[22], Italy [23], and Saudi Arabia [19] detect the intact OC
polypeptide and the N-terminal-Mid OC fragment, as
does the assay used in the present study.
Serum OC concentrations are further affected by eth-
nicity. In a study conducted in 2313 pre- or early peri-
menopausal Caucasian, African American, Chinese, and
Japanese women serum OC concentrations were higher in
Caucasian women than in all other ethnic groups [43].
Ethnic differences in serum OC concentrations may thus
explain the lower reference intervals obtained in women
from Iran (30–40 years: 3.46-19.95 ng/mL; 40–50 years:
2.88-26.30) [21] compared to those obtained in women
from the U.K. [22], although serum osteocalcin concentra-
tions were measured with the same assay. The Iranian
study [21] also reported reference intervals for men. The
reference limits for men aged 30 years and older were
lower than those obtained in our study, probably due to
ethnic differences.
In the current European guidance for the diagnosis and
management of osteoporosis in postmenopausal women
[3] P1NP, but not OC, is recommended for the laboratory
assessment of bone formation. Nevertheless, normative,
method-specific OC data can be applied to assess indivi-
dual OC levels. Moreover, normative OC data may be use-
ful to investigate the relation between OC and energy
metabolism [44,45], as OC has been suggested to be a bio-
marker for insulin resistance [44].
Our study has several strengths and limitations.
Strengths include the large sample size of extensively
characterized study participants. Moreover, all laboratory
measurements were performed in a central laboratory by
trained personnel according to the manufacturers’ rec-
ommendations. A major limitation of our study is the
lack of BMD measurement in our study participants.
Thus, we could not verify whether subjects who did not
Hannemann et al. BMC Endocrine Disorders 2013, 13:11 Page 8 of 9
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aware of an existing osteoporosis. This may have led to
the inclusion of subjects with unknown osteoporosis in
the reference population and to inaccuracies in the esti-
mated reference intervals. Another limitation relates to
the definition of menopausal status, which was based on
age and self-reported menstrual cycling. As perimeno-
pause could not be defined, a misclassification of the
respective women as pre- or postmenopausal may have
occurred. This in turn could have biased pre- and post-
menopausal reference intervals. Yet, the consistency of
our results with those reported for premenopausal women
from the U.K. [22] suggests that our study accurately re-
flects the reference ranges for serum OC concentrations
in healthy premenopausal women. Moreover, our refe-
rence ranges are method-sensitive and may not be applic-
able to other methods of OC measurement. In addition,
our sample is restricted to Caucasian subjects. It may
therefore not be appropriate to apply our reference ranges
to other ethnicities.
Conclusions
We presented reference intervals for serum OC concen-
trations measured by the IDS-iSYS N-Mid Osteocalcin
assay for men as well as for pre- and postmenopausal
women from Northeast Germany. In addition to age and
sex-related differences, we further detected an influence
of oral contraceptives, hormone replacement therapy,
diabetes mellitus, and BMI on serum OC concentrations
in healthy Caucasian subjects.
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